Cancer Genetics, BeiGene Ink Clinical Trial Services Deal | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics (CGI) announced today that it has signed an agreement to provide target identification and biomarker discovery services to cancer drug developer BeiGene.

BeiGene currently has several clinical-stage oncology drugs under development — both as monotherapies and in combination regimens — including ones targeting Bruton's tyrosine kinase, the immune checkpoint receptor PD-1, and the PARP family of proteins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.

Sponsored by
Personal Genome Diagnostics

This webinar will provide an overview of genomic alterations that play a role in immunotherapy response.

Sponsored by

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.